MORRIS PLAINS, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced that Mr. Don C. Stark has been appointed to the
Company's Board of Directors. Mr. Stark is the Chief Executive Officer and
President of Whistler Associates, a marketing and strategic planning
consulting firm for companies focused on oncology. Prior to founding Whistler
Associates, Inc., in 1996, Mr. Stark held various market research, marketing
and business development positions at Bristol-Myers Oncology Division,
Immunex, and Repligen, all in the fields of oncology and immunology. Mr.
Stark is also a founder and member of the Board of Directors of Strategic
Answers Inc., a forecasting and information service provider to the
pharmaceutical industry.
Mr. Stark stated: "I am excited about the prospects for Immunomedics.
Although the Company has long been known for its inroads in the treatment of
cancer with four therapeutic candidates currently in the clinic, Immunomedics
has recently achieved a milestone in the treatment of autoimmune disease with
the FDA's award of fast track designation of epratuzumab for lupus therapy.
The Company also has a very robust product pipeline of novel agents in various
stages of development. I look forward to working closely with the Company in
pursuit of its growth strategy."
Dr. David M. Goldenberg, Chairman of the Board and founder of the Company,
remarked: "We are delighted to have such an experienced and capable
pharmaceutical marketing executive as Don join us. His commercial development
experience in the fields of oncology and immunology are of particular value to
us as we advance our therapeutic product candidates and seek partnering
opportunities for their commercialization."
Immunomedics is a biopharmaceutical company focused on the development of
monoclonal, antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases. We have developed a number of advanced
proprietary technologies that allow us to create humanized antibodies that can
be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create
highly targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We believe that our portfolio of intellectual property, which
includes approximately 90 issued patents in the United States, and more than
250 other issued patents worldwide, protects our product candidates and
technologies.
This release, in addition to historical information, contains forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve
significant risks and uncertainties and actual results could differ materially
from those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, risks associated with new product
development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the fiscal year ended June 30,
2004. The Company is not under any obligation, and the Company expressly
disclaims any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise.
Company Contact: Chau Cheng, Associate Director, Investor Relations &
Business Analysis, (973) 605-8200, extension 123. Visit the Company's web site
at http://www.immunomedics.com.
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Chau Cheng, Associate Director, Investor
Relations & Business Analysis of Immunomedics, Inc.,
+1-973-605-8200, ext. 123
|
